Product Images Clopidogrel

This is a statistical table showing the results of a study on the effectiveness of Clopidogrel and Aspirin in patients with different conditions (Stroke, MI, PAD). The table displays the number of patients, percentage of those who benefited from each treatment (Favors), and their corresponding qualifying condition. The last line shows the overall results. The last row mentioned is the Hazard Ratio calculated for different years.*

This is a chart showing the cumulative event rate for cardiovascular death, myocardial infarction, and stroke for those taking a placebo with aspirin versus those taking clopidogrel with aspirin. Other standard therapies were also used as appropriate. The chart shows that there was a significant difference in the event rate between the two groups. The data was tracked for several months.*

The text appears to show statistics related to clinical trials of a drug called Clopidogrel. The trials involved a placebo group and a group treated with Clopidogrel, and measured the percentage of deaths in each group before the first discharge. The text indicates that the Clopidogrel group had a lower percentage of deaths (7.5%) compared to the placebo group (3.1%), which resulted in a 7% proportional risk reduction (with a p-value of 0.03). The data is presented in relation to the number of days since randomization, with a maximum time of 28 days.*

This text describes data from a study comparing the use of placebo versus clopidogrel in reducing the risk of death, reinfarction or stroke before a patient is discharged from the hospital. The number of patients who experienced an event is provided for each group, along with the proportional risk reduction for clopidogrel compared to placebo. The results were statistically significant (p=0.002). The graph shows the number of days since randomization up to 28 days.*

This document appears to be a statistical report providing information on a clinical trial related to a medication called Clopidogrel. The report includes data on subgroups of participants in the trial, such as their gender, age, blood pressure, and whether they were given a fibrinolytic agent or not. The report also includes figures regarding the effectiveness of Clopidogrel versus Placebo. However, the document seems incomplete as important headings of the column are not available.*

This text presents a comparison of the cumulative event rate for fatal or non-fatal vascular events between aspirin and clopidogrel. The data shows a statistical significance (P=0.045) in favor of one of the treatments but the specific results are not available. The data is presented in the form of a graph with months of follow-up on the x-axis and cumulative event rate on the y-axis.*

This appears to be a combination of two unrelated text blocks. The first block of text reads "Dachaged by Buyant Ranch Prcpach Bunbank, 04 91508" which is not clear what it means. The second block appears to be related to medication and reads "Clopidogrel PINK OVAL TV;7314". It seems to describe a 75 mg tablet to be kept tightly closed at room temperature between 20°-25°C (68°-77°F) that can be compared to Plavix 75mg Tablet. The tablet is produced by Teva Pharmaceutical Industries Ltd. The set contains 90 tablets, and the NDC code is 6362947281 04728901523487.*